IDEXX Laboratories, Inc. IDXX is set to release third-quarter 2025 results on Nov. 3, before the opening bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $3.63, which surpassed the Zacks Consensus Estimate by 9.67%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.08%.
IDXX’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.07 billion, indicating an increase of 9.8% from the year-ago figure.
The Zacks Consensus Estimate for EPS stands at $3.14, implying a rise of 12.1% from the year-ago figure.
Estimate Revision Trend Ahead of IDXX’s Q3 Earnings
Estimates for third-quarter earnings have remained stable at $3.14 in the past 60 days.
Here’s a brief overview of the performance of the pet healthcare innovator, leading up to this announcement.
Factors Shaping IDXX’s Q3 Performance
Companion Animal Group (“CAG”)
The business is expected to have significantly contributed to IDEXX’s top line in the third quarter of 2025, thanks to continued strong global execution. CAG Diagnostics' recurring revenues are likely to have benefited from higher price realisation and increased volumes, supported by an expanded menu of available tests, high customer retention rates, and new business gains. However, growth may have been limited by evolving macroeconomic and sector dynamics, with lingering inflationary impacts continuing to pressure U.S. same-store clinical visits.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote
Growing adoption of IDEXX’s innovations, such as the Catalyst Pancreatic Lipase, launched globally last year, may have also contributed. Furthermore, Global Reference Lab revenues in the third quarter are likely to have received a positive contribution from the IDEXX Cancer Dx, a unique diagnostic panel for early detection of canine lymphoma.
The company is also expected to have gained from robust placements of its premium instruments portfolio, particularly the new IDEXX inVue Dx Analyzer. Following its broad commercial availability since April, the AI-powered platform has seen stronger-than-anticipated adoption, underpinning its role in reshaping point-of-care cytology testing. Besides, the expansion of the global premium instrument installed base may have boosted CAG Diagnostics services and accessories revenue. In the third quarter of 2025, growth in veterinary software and diagnostic imaging revenues is expected to have been backed by both recurring revenues and benefits from ongoing momentum in the cloud-based software installations.
Going by the Zacks Consensus Estimate, IDEXX’s CAG business revenues are expected to increase 10% year over year in the third quarter of 2025.
Water
The segment is likely to have benefited from higher testing volumes, mainly in Europe and the Asia Pacific, as well as from placements of instruments, including the new UA Viewer Plus. Higher price realization is expected to have also contributed.
The Zacks Consensus Estimate for the segment’s revenues implies 8.6% year-over-year growth.
Livestock, Poultry and Dairy (“LPD”)
The division is also likely to have gained from high test volumes in the Asia Pacific and North America, along with favorable price realization.
The Zacks Consensus Estimate for LPD revenues indicates a 5% year-over-year increase in the third quarter of 2025.
What Our Model Says About IDXX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is exactly the case here, as you can see below:
Earnings ESP: IDEXX Laboratories has an Earnings ESP of +0.23%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks Rank #1 stocks here.
Other Top MedTech Picks
Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
Exact Sciences EXAS has an Earnings ESP of +56.25% and a Zacks Rank #1. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. The Zacks Consensus Estimate for the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter figure.
ANI Pharmaceuticals ANIP has an Earnings ESP of +1.15% and a Zacks Rank #2. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. The Zacks Consensus Estimate for ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
Encompass Health EHC has an Earnings ESP of +3.17% and a Zacks Rank #2. The company is slated to release third-quarter 2025 results on Oct. 29.
EHC’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.02%. The Zacks Consensus Estimate for the company’s third-quarter EPS is anticipated to increase 15.5% from the year-ago quarter figure.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
Encompass Health Corporation (EHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
